Abstract:Background: FasL expression was reported to be associated with hepatic metastasis of colorectal cancer. The aim of this study was to study FasL gene expression in colorectal carcinoma and its influences on biological behavior and hepatic metastasis of colorectal carcinoma. Methods: FasL gene expressions were examined with reverse transcriptase-polymerase chain reaction (RT-PCR) in the primary focus of colorectal carcinoma, adjacent cancerous mucosae, and metastasized liver focus from colorectal cancer. HR-8348 cells of human rectal cancer cell line were transfected with FasL cDNA. Cell growth suppression rate and response to 5-FU and carboplatin were observed and analyzed with the MTT method. Results: FasL gene expression was detected in the primary focus of colorectal cancer (n=58), adjacent cancerous mucosae (n=58), and metastasized hepatic tumor tissues (n=28). The positive rate of FasL expression was 24% (14/58), 8% (5/58), and 100% (58/58) in the primary focus, adjacent cancerous mucosae and metastasized hepatic tumor tissues respectively. FasL expression rate in the metastasized hepatic tumor tissues was higher than that in the primary focus (X(2)=43.49, P<0.01) and adjacent cancerous mucosae (X(2)=57.66, P<0.01). In a group of patients with hepatic metastasis, the FasL expression rate in primary focus was higher than that in patients without hepatic metastasis (X(2)=3.96, P<0.05). In vitro study positive expression of FasL was shown in transfected HR-8348 cells. When 5-FU or carboplatin was added, there was a significant difference in growth suppression rate between FasL positive and controlled cancer cells (t=9.02, t=11.93, P<0.01). Under the same concentration of chemotherapeutic agents, the survival rate of FasL positive HR-8348 cells was higher than that of controlled cells. Conclusions: FasL positive cancer cells are powerfully resistant to chemotherapeutic agents. The expression of the FasL gene in colorectal cancer cells is related to immune evasion to escape from being killed by immune cells, showing stronger drug-resistance, and it facilitates hepatic metastasis.

Expression of Fas ligand protein in elderly non-small cell lung cancer and its clinical significance

Expression of Fas ligand protein in human non-small cell lung cancer and its clinical significance

The expression and clinical significance of Fas/FasL on T cells in peripheral blood of elderly patients with primary non-small cell lung cancer

Expression of Fas/Fasl Gene Protein and Its Chinical Significance in Human Non-small Cell Lung Cancer

Expression and biological significance of Fas and FasL in human non-small cell lung cancer

Expression of Fas/FasL in Lung Cancer and Its Significance.

Functional investigation of Fas ligand expressions in human non-small cell lung cancer cells and its clinical implications.

[The Correlation Between DNA Content and Fas Antigen in Non-Small Cell Lung Cancer].

Considering Fas ligand as a target for therapy.

Fas Ligand Expression in Colon Cancer: A Possible Mechanism of Tumor Immune Privilege

[Expression of Fas and P53 Protein in Resected Non-Small Cell Lung Cancer and Its Prognostic Significance].

Clinical Significance of Fas and FasL Protein Expression in Gastric Carcinoma and Local Lymph Node Tissues

Clinicopathological Significance of Fas and Fas Ligand Expressions in Esophageal Cancer.

The significance of FasL expression in immune escape of colorectal carcinoma

FasL Expression in Human Colon Carcinomas

Analysis of Fas and Fas Ligand expression and function in lung cancer cell lines

[The influence of FasL gene expression upon hepatic metastasis of colorectal carcinoma]

Significance of Fas and FasL Protein Expression in Cardiac Carcinoma and Local Lymph Node Tissues.

The Expression of Fas,FasL in Laryngeal Carcinoma and Its Clinical Significance

[The role of Fas/Fas ligand in tumorgenesis, immune escape, and counterattack in colonic cancer].

Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma